X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-04 | BTAI | O'Neill Vincent | See Remarks | S - Sale+OE | $2.62 | -165 | 5,408 | -3% | -$432 | |||||
| D | 2024-04-04 | BTAI | Mehta Vimal | CEO, Pres | S - Sale+OE | $2.62 | -5,268 | 8,592,314 | 0% | -$13,823 | |||||
| D | 2024-04-04 | BTAI | Steinhart Richard I | CFO | S - Sale+OE | $2.64 | -1,069 | 4,765 | -18% | -$2,817 | |||||
| D | 2024-04-04 | BTAI | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $2.64 | -1,008 | 2,992 | -25% | -$2,656 | |||||
| D | 2024-04-04 | BTAI | Rodriguez Javier | See Remarks | S - Sale+OE | $2.64 | -1,012 | 7,672 | -12% | -$2,667 | |||||
| D | 2024-04-04 | BTAI | Yocca Frank | Chief Scientific Officer | S - Sale+OE | $2.64 | -1,067 | 12,763 | -8% | -$2,812 | |||||
| DM | 2023-06-15 | BTAI | Mehta Vimal | CEO, Pres | S - Sale+OE | $20.86 | -60,000 | 41,903 | -59% | -$1,251,727 | |||||
2023-05-22 | BTAI | Mehta Vimal | CEO, Pres | S - Sale | $25.79 | -6,500 | 39,294 | -14% | -$167,641 | ||||||
| D | 2023-05-15 | BTAI | Steinhart Richard I | CFO | S - Sale+OE | $27.17 | -5,000 | 1,500 | -77% | -$135,864 | |||||
| D | 2023-05-15 | BTAI | Rodriguez Javier | See Remarks | S - Sale+OE | $27.32 | -1,785 | 4,350 | -29% | -$48,765 | |||||
| D | 2023-04-06 | BTAI | Nandabalan Krishnan | Dir, 10% | S - Sale+OE | $17.32 | -60,000 | 8,546,750 | -1% | -$1,039,200 | |||||
| DM | 2023-03-20 | BTAI | Mehta Vimal | CEO, Pres | S - Sale+OE | $18.97 | -64,500 | 8,564,644 | -1% | -$1,223,313 | |||||
| D | 2023-03-15 | BTAI | Steinhart Richard I | CFO | S - Sale+OE | $19.50 | -2,084 | 1,500 | -58% | -$40,638 | |||||
| D | 2023-03-15 | BTAI | Yocca Frank | Chief Scientific Officer | S - Sale+OE | $19.69 | -985 | 9,496 | -9% | -$19,396 | |||||
| D | 2023-03-15 | BTAI | O'Neill Vincent | Chief Medical Officer | S - Sale+OE | $19.70 | -845 | 1,239 | -41% | -$16,642 | |||||
| D | 2023-03-15 | BTAI | Rodriguez Javier | See Remarks | S - Sale+OE | $19.63 | -950 | 1,135 | -46% | -$18,644 | |||||
2023-01-20 | BTAI | Yocca Frank | Chief Scientific Officer | S - Sale | $30.00 | -50,000 | 8,397 | -86% | -$1,500,000 | ||||||
| D | 2023-01-20 | BTAI | O'Neill Vincent | Chief Medical Officer | S - Sale+OE | $30.00 | -29,713 | 0 | -100% | -$891,390 | |||||
| DM | 2023-01-04 | BTAI | Nandabalan Krishnan | Dir, 10% | S - Sale+OE | $22.01 | -60,000 | 8,546,750 | -1% | -$1,320,876 | |||||
| DM | 2022-12-15 | BTAI | Mehta Vimal | CEO, Pres, 10% | S - Sale+OE | $19.69 | -60,000 | 8,558,707 | -1% | -$1,181,498 | |||||
| DM | 2022-11-10 | BTAI | Nandabalan Krishnan | Dir, 10% | S - Sale+OE | $15.00 | -60,000 | 8,546,750 | -1% | -$900,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |